Arzneimittelforschung 2012; 62(10): 449-456
DOI: 10.1055/s-0032-1314877
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Development and Validation of a Liquid Chromatography-tandem Mass Spectrometry Method for the Simultaneous Determination of Acrivastine and Pseudoephedrine in Human Plasma and its Application in Pharmacokinetics

J.-C. He
1   Department of Pharmacy, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, PR China
,
E.-F. Feng
1   Department of Pharmacy, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, PR China
,
M. Liu
2   Department of Gastroenterology, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, PR China
,
H.-L. Li
1   Department of Pharmacy, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, PR China
,
M. Tian
1   Department of Pharmacy, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, PR China
,
Q. Zhang
1   Department of Pharmacy, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, PR China
,
L.-C. Dong
1   Department of Pharmacy, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, PR China
,
G.-L. Xu
1   Department of Pharmacy, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, PR China
› Author Affiliations
Further Information

Publication History

received 14 February 2012

accepted 14 May 2012

Publication Date:
30 August 2012 (online)

Abstract

A specific, sensitive and accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed for the simultaneous determination of acrivastine and pseudoephedrine in human plasma samples. Plasma samples were processed and analyzed on a Phenomenex Luna 3 μ CN 100A column (150 mm×2.0 mm) eluted with the mobile phase consisting of methanol and 0.01 mol/L ammonium acetate water solution containing 0.1% formic acid (45:55, v/v) at a flow rate of 0.2 mL/min. The analytes were detected by positive ion electrospray ionization in multiple reaction monitoring mode. The transitions of m/z 349→278, m/z 166→148 and m/z 256→167 were monitored for acrivastine, pseudoephedrine and diphenhydramine (IS), respectively. The method was specific and sensitive with a lower limit of quantitation (LLOQ) of 1.52 ng/mL for acrivastine and 8.13 ng/mL for pseudoephedrine. The method showed good linearity in the range of 1.52~606.0 0 ng/mL for acrivastine and 8.13~813.12 ng/mL for pseudoephedrine (r≥0.996). The mean recovery were ranged 91.82% ~ 98.46% for acrivastine and 90.77% ~ 92.05% for pseudoephedrine. Validation results, such as accuracy, precision and repeatability were within the required limits. The method was successfully applied in a pharmacokinetic study of the acrivastine and pseudoephedrine hydrochloride compound capsule in humans.

 
  • References

  • 1 Yang BF, Su FD, Li J. Pharmacology. Version 6. Beijing: People’s Medical Publishing House; 2004: 316-318
  • 2 Wang W, Wang GJ, Sun JG. Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-mass spectrometry and the pharmacokinetics study. Chinese Journal of New Drμgs 2005; 14 (07) 898-902
  • 3 Hu X, hang LF, Zhang H. Simultaneous Determination of Cloperastine, Chlorpheniramine and Psedoephedrine Concentrations in Human Plasma by LC-MS. Chinese Journal of Modern Applied Pharmacy 2009; 26 (02) 106-108
  • 4 Li XN, Xu JN, Chen WL. Determination of essential components of compound of loratadine, paracetamol and pseudoephedrine by liquid chromatography-tandem spectrometry and its pharmacokinetics. Chinese Journal of Clinical Pharmacy 2008; 17 (01) 9-14
  • 5 Han Y, Chen XY, Xie ZY. Simultaneous determination of pseudoephedrine and diphenhydramine in human plasma by liquid chromatography-tandem mass spectrometry. Acta Pharmaceutica Sinica 2003; 38 (01) 67-70
  • 6 Huang FY, Liu SJ, Liu BG. Determination of pseudephedrine in human plasma by LC-MS/MS and its pharmacokinetics. Central South Pharmacy 2009; 7 (11) 835-840
  • 7 Xu SS, Zheng J, Xu HR. Simultaneous determination of cetirizine and pseudoephedrine in human plasma by liquid chromatography-tandem mass spectrometry[J]. Chinese Journal of Clinical Pharmacy 2007; 16 (02) 81-84
  • 8 Tan F, Jiang XH, Ren J. Determination of pseudoephedrine hydrochloride in human plasma by LC-MS/MS. West China Medical Journal 2010; 25 (01) 100-102
  • 9 Liu Y, Ren XH. Determination of Pseudoephedrine Hydrochloride in Human Plasma by LC/MS/MS. Herald of Medicine 2010; 29 (12) 1563-1565
  • 10 Gunn J, Kriger S, Terrell AR. Identification and quantitation of amphetamine, methamphetamine, MDMA, pseudoephedrine, and ephedrine in blood, plasma, and serum using gas chromatography-mass spectrometry (GC/MS). Methods Mol Biol 2010; 603: 37-43
  • 11 Liu G, Wang H, Zhang XZ. Determination of pseudoephedrine in human serum by HPCE. China Pharmacist 2006; 9 (07) 617-618
  • 12 Zhou YD, He HX, Yang H. Pharmacokinetics and bioequivalence of acrivastine capsule in healthy subjects [J]. Chin J New Drμgs Clin Rem 2007; 26 (04) 249-252
  • 13 Collins BR, Gu X. Quantification of antihistamine acrivastine in plasma by solid-phase extraction and high-performance liquid chromatography. J Pharm Biomed Anal 2007; 43 (01) 293-297
  • 14 Chang SY, Nelson FR, Findlay JW et al. Quantitative gas chromatographic-mass spectrometric analysis of acrivastine and a metabolite in human plasma. J Chromatogr 1989; 29 (497) 288-295
  • 15 Altuntas TG, Zanooz SS, Nebioglu D. Quantitative determination of acrivastine and pseudoephedrine hydrochloride in pharmaceutical formulation by high performance liquid chromatography and derivative spectrophotometry. J Pharm Biomed Anal 1998; 17 (01) 103-109
  • 16 Gu X, Li H, Macnair KR. Simultaneous analysis of the H1-antihistamine acrivastine and the decongestant pseudoephedrine hydrochloride by high-performance liquid chromatography. J Pharm Biomed Anal 2005; 37 (04) 663-667
  • 17 Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) 2001 Center for Veterinary Medicine (CV), May 2001. http://www/fda.gov/cder/guidance/index.htm